Expression of the lung resistance protein (LRP) in primary breast cancer.

Abstract

BACKGROUND:

To determine the clinical significance of the lung resistance protein (LRP) in breast cancer, we have studied its expression in primary breast carcinomas (n = 99) and assessed the association of this expression with clinical parameters of the patients.

MATERIALS AND METHODS:

LRP expression was immunohistochemically determined by means of the monoclonal antibody LRP-56 on frozen tumor sections.

RESULTS:

LRP expression was negative in 12%, low in 20%, intermediate in 47% and high in 21% of the carcinomas. LRP expression was independent of age of the patients, histology, tumor grade, estrogen receptor as well as progesterone receptor status, tumor size and lymph node involvement. Kaplan-Meier analyses revealed that both overall survival and disease-free survival were independent of the degree of LRP expression.

CONCLUSIONS:

LRP is frequently expressed in breast carcinomas, but is neither associated with known prognostic factors, nor a prognostic factor by itself.

• Authors: G Pohl, M Filipits, R W Suchomel, T Stranzl, D Depisch, R Pirker
• Journal: Anticancer research (Anticancer Res) 1999 Nov-Dec Vol. 19 Issue 6B Pg. 5051-5 ISSN: 0250-7005 [Print] Greece
• PMID: 10697509 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Neoplasm Proteins
• Vault Ribonucleoprotein Particles
• major vault protein

Topics

• Adult
• Aged
• Aged, 80 and over
• Breast Neoplasms (metabolism)
• Female
• Humans
• Middle Aged
• Neoplasm Proteins (metabolism)
• Prognosis
• Survival Rate
• Vault Ribonucleoprotein Particles (metabolism)